Skip to main content
SpringerLink
Log in

Neuroprotection in Parkinson’s Disease

  • Chapter
  • First Online:
The Handbook of Neuroprotection

  • 1214 Accesses

Abstract

Parkinson’s disease (PD) is a progressive disorder of the CNS characterized by tremor at rest, bradykinesia (slowness of movement), rigidity, and flexed posture. Pathologically, the key deficit has been considered to be loss of pigmented dopamine-producing neurons in the substantia nigra. Although the cause of the disease remains unknown, considerable progress has been made to expand our knowledge of the clinical features, neuropathology, and treatment of the disease since the description of the disease by James Parkinson about 200 years ago.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 149.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 199.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Ahlskog JE, Uitti RJ. Rasagiline, Parkinson neuroprotection, and delayed-start trials: still no satisfaction? Neurology 2010;74:1143–8.

    Article  PubMed  CAS  Google Scholar 

  • Akaike A, Takada-Takatori Y, Kume T, Izumi Y. Mechanisms of neuroprotective effects of nicotine and acetylcholinesterase inhibitors: role of alpha4 and alpha7 receptors in neuroprotection. J Mol Neurosci 2010;40:211–6.

    Article  PubMed  CAS  Google Scholar 

  • Aleyasin H, Rousseaux MW, Marcogliese PC, et al. DJ-1 protects the nigrostriatal axis from the neurotoxin MPTP by modulation of the AKT pathway. Proc Natl Acad Sci U S A 2010;107:3186–91.

    Article  PubMed  CAS  Google Scholar 

  • Androutsellis-Theotokis A, Rueger MA, Mkhikian H, et al. Targeting neural precursors in the adult brain rescues injured dopamine neurons. Proc Natl Acad Sci U S A 2009;106:13570–5.

    Article  PubMed  CAS  Google Scholar 

  • Bar-Am O, Weinreb O, Amit T, Youdim MB. The neuroprotective mechanism of 1-(R)-aminoindan, the major metabolite of the anti-Parkinsonian drug rasagiline. J Neurochem 2010;112:1131–7.

    Article  PubMed  CAS  Google Scholar 

  • Benner EJ, Mosley RL, Destache CJ, et al. Therapeutic immunization protects dopaminergic neurons in a mouse model of Parkinson’s disease. Proc Natl Acad Sci U S A 2004;101:9435–40.

    Article  PubMed  CAS  Google Scholar 

  • Bjorklund LM, Sanchez-Pernaute R, Chung S, et al. Embryonic stem cells develop into functional dopaminergic neurons after transplantation in a Parkinson rat model. Proc Natl Acad Sci U S A 2002;99:2344–9.

    Article  PubMed  CAS  Google Scholar 

  • Bousquet M, Saint-Pierre M, Julien C, et al. Beneficial effects of dietary omega-3 polyunsaturated fatty acid on toxin-induced neuronal degeneration in an animal model of Parkinson’s disease. FASEB J 2008;22:1213–25.

    Article  PubMed  CAS  Google Scholar 

  • Caccia C, Maj R, Calabresi M, et al. Safinamide: from molecular targets to a new anti-Parkinson drug. Neurology 2006;67(7 Suppl 2):S18–23.

    Article  PubMed  CAS  Google Scholar 

  • Caudle WM, Richardson JR, Wang MZ, et al. Reduced vesicular storage of dopamine causes progressive nigrostriatal neurodegeneration. J Neurosci 2007;27:8138–48.

    Article  PubMed  CAS  Google Scholar 

  • Chan CS, Guzman JN, Ilijic E, et al. ‘Rejuvenation’ protects neurons in mouse models of Parkinson’s disease. Nature 2007;447:1081–6.

    Article  PubMed  CAS  Google Scholar 

  • Chan CS, Gertler TS, Surmeier DJ. A molecular basis for the increased vulnerability of substantia nigra dopamine neurons in aging and Parkinson’s disease. Mov Disord 2010;25(Suppl 1):S63–70.

    Article  PubMed  Google Scholar 

  • Chen S, Zhang X, Yang D, et al. D2/D3 receptor agonist ropinirole protects dopaminergic cell line against rotenone-induced apoptosis through inhibition of caspase- and JNK-dependent pathways. FEBS Lett 2008b;582:603–10.

    Article  PubMed  CAS  Google Scholar 

  • Chen PC, Vargas MR, Pani AK, et al. Nrf2-mediated neuroprotection in the MPTP mouse model of Parkinson’s disease: critical role for the astrocyte. Proc Natl Acad Sci U S A 2009;106:2933–8.

    Article  PubMed  CAS  Google Scholar 

  • Chetsawang B, Kooncumchoo P, Govitrapong P, Ebadi M. 1-Methyl-4-phenyl-pyridinium ion-induced oxidative stress, c-Jun phosphorylation and DNA fragmentation factor-45 cleavage in SK-N-SH cells are averted by selegiline. Neurochem Int 2008;53:283–8.

    Article  PubMed  CAS  Google Scholar 

  • Chung CY, Koprich JB, Hallett PJ, Isacson O. Functional enhancement and protection of ­dopaminergic terminals by RAB3B overexpression. Proc Natl Acad Sci U S A 2009;106:22474–9.

    Article  PubMed  CAS  Google Scholar 

  • Costa RM, Lin SC, Sotnikova TD, et al. Rapid alterations in corticostriatal ensemble coordination during acute dopamine-dependent motor dysfunction. Neuron 2006;52:359–69.

    Article  PubMed  CAS  Google Scholar 

  • de la Fuente-Fernández R, Schulzer M, Mak E, Sossi V. Trials of neuroprotective therapies for Parkinson’s disease: problems and limitations. Parkinsonism Relat Disord 2010;16:365–9.

    Article  PubMed  Google Scholar 

  • Diaz-Nido J. NLX-P101, an adeno-associated virus gene therapy encoding glutamic acid decarboxylase, for the potential treatment of Parkinson’s disease. Curr Opin Investig Drugs 2010;11:813–22.

    PubMed  CAS  Google Scholar 

  • Ekstrand MI, Terzioglu M, Galter D, et al. Progressive Parkinsonism in mice with respiratory-chain-deficient dopamine neurons. Proc Natl Acad Sci U S A 2007;104:1325–30.

    Article  PubMed  CAS  Google Scholar 

  • Etminan M, Gill GS, Samii A. Intake of vitamin E, vitamin C, and carotenoids and the risk of Parkinson’s disease: a meta-analysis. Lancet Neurol 2005;4:362–5.

    Article  PubMed  CAS  Google Scholar 

  • Faherty CJ, Raviie Shepherd K, Herasimtschuk A, et al. Environmental enrichment in adulthood eliminates neuronal death in experimental Parkinsonism. Brain Res Mol Brain Res 2005;134:170–9.

    Article  PubMed  CAS  Google Scholar 

  • Feng LR, Maguire-Zeiss KA. Gene therapy in Parkinson’s disease: rationale and current status. CNS Drugs 2010;24:177–92.

    Article  PubMed  CAS  Google Scholar 

  • Fumagalli F, Racagni G, Riva MA. Shedding light into the role of BDNF in the pharmacotherapy of Parkinson’s disease. Pharmacogenomics J 2006;6:95–104.

    Article  PubMed  CAS  Google Scholar 

  • Gasmi M, Herzog CD, Brandon EP, et al. Striatal delivery of neurturin by CERE-120, an AAV2 vector for the treatment of dopaminergic neuron degeneration in Parkinson’s disease. Mol Ther 2007;15:62–8.

    Article  PubMed  CAS  Google Scholar 

  • Gill SS, Patel NK, Hotton GR, et al. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat Med 2003;9:589–95.

    Article  PubMed  CAS  Google Scholar 

  • Gu M, Irvani MM, Cooper JM, et al. Pramipexole protects against apoptotic cell death by non-dopaminergic mechanisms. J Neurochem 2004;91:1075–81.

    Article  PubMed  CAS  Google Scholar 

  • Hamamichi S, Rivas RN, Knight AL, et al. Hypothesis-based RNAi screening identifies neuroprotective genes in a Parkinson’s disease model. Proc Natl Acad Sci U S A 2008;105:728–33.

    Article  PubMed  CAS  Google Scholar 

  • Hauser RA, Lew MF, Hurtig HI, et al. TEMPO Open-label Study Group. Long-term outcome of early versus delayed rasagiline treatment in early Parkinson’s disease. Mov Disord 2009;24:564–73.

    Article  PubMed  Google Scholar 

  • Izumi Y, Sawada H, Yamamoto N, et al. Novel neuroprotective mechanisms of pramipexole, an anti-Parkinson drug, against endogenous dopamine-mediated excitotoxicity. Eur J Pharmacol 2007;557:132–40.

    Article  PubMed  CAS  Google Scholar 

  • Jain KK. Drug Delivery in CNS Disorders. Jain PharmaBiotech Publications, Basel, 2010a.

    Google Scholar 

  • Jain KK. Pramipexole. In Gilman S (ed) MedLink Neurology. Medlink Publishing Corporation, San Diego, California, 2010b.

    Google Scholar 

  • Jain KK. Rasagiline. In Gilman S (ed) MedLink Neurology. Medlink Publishing Corporation, San Diego, California, 2010c.

    Google Scholar 

  • Jain KK. Selegiline. In Gilman S (ed) MedLink Neurology. Medlink Publishing Corporation, San Diego, California, 2010d.

    Google Scholar 

  • Jain KK. Cell Therapy: Technologies, Companies and Markets. Jain PharmaBiotech Publications, Basel, 2010e.

    Google Scholar 

  • Jain KK. Scientific and Commercial Aspects of Neuroprotection. Jain PharmaBiotech Publications, Basel, 2010f.

    Google Scholar 

  • Joyce JN, Woolsey C, Ryoo H, et al. Low dose pramipexole is neuroprotective in the MPTP mouse model of Parkinson’s disease, and downregulates the dopamine transporter via the D3 receptor. BMC Biol 2004;2:22.

    Article  PubMed  Google Scholar 

  • Kaplitt MG, Feigin A, Tang C, et al. Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson’s disease: an open label, phase I trial. Lancet 2007;369:2097–105.

    Article  PubMed  CAS  Google Scholar 

  • Knekt P, Kilkkinen A, Rissanen H, et al. Serum vitamin D and the risk of Parkinson disease. Arch Neurol 2010;67:808–11.

    Article  PubMed  Google Scholar 

  • Koob AO, Ubhi K, Paulsson JF, et al. Lovastatin ameliorates alpha-synuclein accumulation and oxidation in transgenic mouse models of alpha-synucleinopathies. Exp Neurol 2010;221:267–74.

    Article  PubMed  CAS  Google Scholar 

  • Lindholm P, Voutilainen MH, Lauren J, et al. Novel neurotrophic factor CDNF protects and rescues midbrain dopamine neurons in vivo. Nature 2007;448:73–7.

    Article  PubMed  CAS  Google Scholar 

  • Liu F, Nguyen JL, Hulleman JD, et al. Mechanisms of DJ-1 neuroprotection in a cellular model of Parkinson’s disease. J Neurochem 2008;105:2435–53.

    Article  PubMed  CAS  Google Scholar 

  • Lo Bianco C, Schneider BL, Bauer M, et al. Lentiviral vector delivery of parkin prevents dopaminergic degeneration in an alpha-synuclein rat model of Parkinson’s disease. Proc Natl Acad Sci U S A 2004;101:17510–5.

    Article  PubMed  CAS  Google Scholar 

  • Ma J, Shaw VE, Mitrofanis J, et al. Does melatonin help save dopaminergic cells in MPTP-treated mice? Parkinsonism Relat Disord 2009;15:307–14.

    Article  PubMed  Google Scholar 

  • Madhavan L, Daley BF, Paumier KL, Collier TJ. Transplantation of subventricular zone neural precursors induces an endogenous precursor cell response in a rat model of Parkinson’s disease. J Comp Neurol 2009;515:102–15.

    Article  PubMed  Google Scholar 

  • Maraganore DM, de Andrade M, Lesnick TG, et al. High-resolution whole-genome association study of Parkinson disease. Am J Hum Genet 2005;77:685–93.

    Article  PubMed  CAS  Google Scholar 

  • Marks WJ Jr, Ostrem JL, Verhagen L, et al. Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson’s disease: an open-label, phase I trial. Lancet Neurol 2008;7:400–8.

    Article  PubMed  Google Scholar 

  • Masliah E, Rockenstein E, Adame A, et al. Effects of α-synuclein immunization in a mouse model of Parkinson’s disease. Neuron 2005;46:857–68.

    Article  PubMed  CAS  Google Scholar 

  • Maswood N, Young J, Tilmont E, et al. Caloric restriction increases neurotrophic factor levels and attenuates neurochemical and behavioral deficits in a primate model of Parkinson’s disease. Proc Natl Acad Sci U S A 2004;101:18171–6.

    Article  PubMed  CAS  Google Scholar 

  • Moran LB, Duke DC, Deprez M, et al. Whole genome expression profiling of the medial and lateral substantia nigra in Parkinson’s disease. Neurogenetics 2006;7:1–11.

    Article  PubMed  CAS  Google Scholar 

  • Müller T. New small molecules for the treatment of Parkinson’s disease. Expert Opin Investig Drugs 2010;19:1077–86.

    Article  PubMed  Google Scholar 

  • NINDS NET-PD Investigators. A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease. Neurology 2006;66:664–71.

    Article  Google Scholar 

  • Nutt JG, Burchiel KJ, Comella CL, et al. Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. Neurology 2003;60:69–73.

    Article  PubMed  CAS  Google Scholar 

  • Olanow CW, Rascol O, Hauser R, et al. A double-blind, delayed-start trial of rasagiline in Parkinson’s disease. N Engl J Med 2009;361:1268–78.

    Article  PubMed  CAS  Google Scholar 

  • Onofrj M, Bonanni L, Thomas A. An expert opinion on safinamide in Parkinson’s disease. Expert Opin Investig Drugs 2008;17:1115–25.

    Article  PubMed  CAS  Google Scholar 

  • Outeiro TF, Kontopoulos E, Altmann S, et al. Sirtuin 2 inhibitors rescue α-synuclein-mediated toxicity in models of Parkinson’s disease. Science 2007;317:516–9.

    Article  PubMed  CAS  Google Scholar 

  • Pan T, Xie W, Jankovic J, Le W. Biological effects of pramipexole on dopaminergic neuron-associated genes: relevance to neuroprotection. Neurosci Lett 2005;377:106–9.

    Article  PubMed  CAS  Google Scholar 

  • Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 2002;287:1653–61.

    Article  Google Scholar 

  • Pinna A. Novel investigational adenosine A2A receptor antagonists for Parkinson’s disease. Expert Opin Investig Drugs 2009;18:1619–31.

    Article  PubMed  CAS  Google Scholar 

  • Quik M, Parameswaran N, McCallum SE, et al. Chronic oral nicotine treatment protects against striatal degeneration in MPTP-treated primates. J Neurochem 2006;98:1866–75.

    Article  PubMed  CAS  Google Scholar 

  • Sapru MK, Yates JW, Hogan S, et al. Silencing of human α-synuclein in vitro and in rat brain using lentiviral-mediated RNAi. Exp Neurol 2006;198:382–90.

    Article  PubMed  CAS  Google Scholar 

  • Schapira A. Safinamide in the treatment of Parkinson’s disease. Expert Opin Pharmacother 2010;11:2261–8.

    Article  PubMed  CAS  Google Scholar 

  • Sharma R, McMillan CR, Tenn CC, Niles LP. Physiological neuroprotection by melatonin in a 6-hydroxydopamine model of Parkinson’s disease. Brain Res 2006;1068:230–6.

    Article  PubMed  CAS  Google Scholar 

  • Van Kampen JM, Eckman CB. Dopamine D3 receptor agonist delivery to a model of Parkinson’s disease restores the nigrostriatal pathway and improves locomotor behavior. J Neurosci 2006;26:7272–80.

    Article  PubMed  Google Scholar 

  • Visanji NP, Orsi A, Johnston TH, et al. PYM50028, a novel, orally active, nonpeptide neurotrophic factor inducer, prevents and reverses neuronal damage induced by MPP+ in mesencephalic neurons and by MPTP in a mouse model of Parkinson’s disease. FASEB J 2008;22:2488–97.

    Article  PubMed  CAS  Google Scholar 

  • Wang Q, Wang PH, McLachlan C, Wong PT. Simvastatin reverses the downregulation of dopamine D1 and D2 receptor expression in the prefrontal cortex of 6-hydroxydopamine-induced Parkinsonian rats. Brain Res 2005;1045:229–33.

    Article  PubMed  CAS  Google Scholar 

  • Whitworth AJ, Theodore DA, Greene JC, et al. Increased glutathione S-transferase activity rescues dopaminergic neuron loss in a Drosophila model of Parkinson’s disease. Proc Natl Acad Sci U S A 2005;102:8024–9.

    Article  PubMed  CAS  Google Scholar 

  • Whone AL, Watts RL, Stoessl AJ, et al. Slower progression of Parkinson’s disease with ropinirole versus levodopa: The REAL-PET study. Ann Neurol 2003;54:93–101.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Jain PharmaBiotech, Blaesiring 7, Basel, 4057, Switzerland

    Kewal K. Jain

Authors
  1. Kewal K. Jain
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kewal K. Jain .

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Jain, K.K. (2011). Neuroprotection in Parkinson’s Disease. In: The Handbook of Neuroprotection. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-61779-049-2_7

Download citation

Publish with us

Policies and ethics

Search

Navigation